Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- A nd paracellular pathways

Journal of Controlled Release

Volumn 228, Issue , 2016, Pages 9-19

  Li, Man ^a   Zhao, Mengnan ^a   Fu, Yao ^a   Li, You ^a   Gong, Tao ^a   Zhang, Zhirong ^a   Sun, Xun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

CD PEI; Intracellular delivery; mRNA vaccination; Nasal epithelial barrier; Paracellular delivery

Indexed keywords

POLYMERS; VACCINES; VIRUSES;

BIOLOGICAL BARRIER; CATIONIC CYCLODEXTRIN; CYTOKINE PRODUCTION; EPITHELIAL BARRIER; INTRACELLULAR DELIVERY; MRNA VACCINATION; PARACELLULAR; POLYMERIC DELIVERY SYSTEMS;

DISEASES;

CYCLODEXTRIN; GLYCOPROTEIN GP 120; MESSENGER RNA; MESSENGER RNA VACCINE; POLYETHYLENEIMINE; RNA VACCINE; UNCLASSIFIED DRUG; DRUG CARRIER; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SEQUENCE; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; MTT ASSAY; NONHUMAN; NOSE CAVITY; PRIORITY JOURNAL; RNA IMMUNIZATION; STATIC ELECTRICITY; TH1 CELL; TH17 CELL; TH2 CELL; TIGHT JUNCTION; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; DOG; GENETICS; HIV INFECTIONS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; MUCOSAL IMMUNITY; NOSE MUCOSA; VACCINATION;

ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; CELL LINE; CYCLODEXTRINS; DOGS; DRUG CARRIERS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; NASAL MUCOSA; POLYETHYLENEIMINE; RNA, MESSENGER; VACCINATION;

EID: 84961595277     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.02.043     Document Type: Article

References (51)

1. W. Fischer, S. Perkins, J. Theiler, T. Bhattacharya, K. Yusim, R. Funkhouser, C. Kuiken, B. Haynes, N.L. Letvin, B.D. Walker, B.H. Hahn, and B.T. Korber Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants Nat. Med. 13 2007 100 106
2. H.X. Liao, R. Lynch, T. Zhou, F. Gao, S.M. Alam, S.D. Boyd, A.Z. Fire, K.M. Roskin, C.A. Schramm, Z. Zhang, J. Zhu, L. Shapiro, J.C. Mullikin, S. Gnanakaran, P. Hraber, K. Wiehe, G. Kelsoe, G. Yang, S.M. Xia, D.C. Montefiori, R. Parks, K.E. Lloyd, R.M. Scearce, K.A. Soderberg, M. Cohen, G. Kamanga, M.K. Louder, L.M. Tran, Y. Chen, F. Cai, S. Chen, S. Moquin, X. Du, M.G. Joyce, S. Srivatsan, B. Zhang, A. Zheng, G.M. Shaw, B.H. Hahn, T.B. Kepler, B.T. Korber, P.D. Kwong, J.R. Mascola, and B.F. Haynes Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus Nature 496 2013 469 476
3. J. Huang, B.H. Kang, M. Pancera, J.H. Lee, T. Tong, Y. Feng, H. Imamichi, I.S. Georgiev, G.Y. Chuang, A. Druz, N.A. Doria-Rose, L. Laub, K. Sliepen, M.J. van Gils, A.T. de la Pena, R. Derking, P.J. Klasse, S.A. Migueles, R.T. Bailer, M. Alam, P. Pugach, B.F. Haynes, R.T. Wyatt, R.W. Sanders, J.M. Binley, A.B. Ward, J.R. Mascola, P.D. Kwong, and M. Connors Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface Nature 515 2014 138 142
4. L. Xu, Y. Liu, Z. Chen, W. Li, Y. Liu, L. Wang, Y. Liu, X. Wu, Y. Ji, Y. Zhao, L. Ma, Y. Shao, and C. Chen Surface-engineered gold nanorods: Promising DNA vaccine adjuvant for HIV-1 treatment Nano Lett. 12 2012 2003 2012
5. Y. Tian, H. Wang, Y. Liu, L. Mao, W. Chen, Z. Zhu, W. Liu, W. Zheng, Y. Zhao, D. Kong, Z. Yang, W. Zhang, Y. Shao, and X. Jiang A peptide-based nanofibrous hydrogel as a promising DNA nanovector for optimizing the efficacy of HIV vaccine Nano Lett. 14 2014 1439 1445
6. S. Kreiter, M. Vormehr, N. van de Roemer, M. Diken, M. Lower, J. Diekmann, S. Boegel, B. Schrors, F. Vascotto, J.C. Castle, A.D. Tadmor, S.P. Schoenberger, C. Huber, O. Tureci, and U. Sahin Mutant MHC class II epitopes drive therapeutic immune responses to cancer Nature 520 2015 692 696
7. S. Mizutani, and R.J. Colonno In vitro synthesis of an infectious RNA from cDNA clones of human rhinovirus type 14 J. Virol. 56 1985 628 632
8. M. Mockey, C. Gonçalves, F.P. Dupuy, F.M. Lemoine, C. Pichon, and P. Midoux mRNA transfection of dendritic cells: Synergistic effect of ARCA mRNA capping with poly (A) chains in cis and in trans for a high protein expression level Biochem. Biophys. Res. Commun. 340 2006 1062 1068
9. A. Yamamoto, M. Kormann, J. Rosenecker, and C. Rudolph Current prospects for mRNA gene delivery Eur. J. Pharm. Biopharm. 71 2009 484 489
10. Q. Hu, M. Wu, C. Fang, C. Cheng, M. Zhao, W. Fang, P.K. Chu, Y. Ping, and G. Tang Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy Nano Lett. 15 2015 2732 2739
11. S. Pascolo Messenger RNA-based vaccines Expert. Opin. Biol. Ther. 4 2004 1285 1294
12. O. Andries, M. De Filette, J. Rejman, S.C. De Smedt, J. Demeester, M. Van Poucke, L. Peelman, C. Peleman, T. Lahoutte, and N.N. Sanders Comparison of the gene transfer efficiency of mRNA/GL67 and pDNA/GL67 complexes in respiratory cells Mol. Pharm. 9 2012 2136 2145
13. G. Tavernier, O. Andries, J. Demeester, N.N. Sanders, S.C. De Smedt, and J. Rejman mRNA as gene therapeutic: How to control protein expression J. Control. Release 150 2011 238 247
14. B. Petsch, M. Schnee, A.B. Vogel, E. Lange, B. Hoffmann, D. Voss, T. Schlake, A. Thess, K.J. Kallen, L. Stitz, and T. Kramps Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection Nat. Biotechnol. 30 2012 1210 1216
15. K. Deng, M. Pertea, A. Rongvaux, L. Wang, C.M. Durand, G. Ghiaur, J. Lai, H.L. McHugh, H. Hao, H. Zhang, J.B. Margolick, C. Gurer, A.J. Murphy, D.M. Valenzuela, G.D. Yancopoulos, S.G. Deeks, T. Strowig, P. Kumar, J.D. Siliciano, S.L. Salzberg, R.A. Flavell, L. Shan, and R.F. Siliciano Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations Nature 517 2015 381 385
16. M. Mockey, E. Bourseau, V. Chandrashekhar, A. Chaudhuri, S. Lafosse, E. Le Cam, V.F. Quesniaux, B. Ryffel, C. Pichon, and P. Midoux mRNA-based cancer vaccine: Prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes Cancer Gene Ther. 14 2007 802 814
17. C. Pollard, J. Rejman, W. De Haes, B. Verrier, E. Van Gulck, T. Naessens, S. De Smedt, P. Bogaert, J. Grooten, G. Vanham, and S. De Koker Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines Mol. Ther. 21 2013 251 259
18. H. Kubler, B. Scheel, U. Gnad-Vogt, K. Miller, W. Schultze-Seemann, F. Vom Dorp, G. Parmiani, C. Hampel, S. Wedel, L. Trojan, D. Jocham, T. Maurer, G. Rippin, M. Fotin-Mleczek, F. von der Mulbe, J. Probst, I. Hoerr, K.J. Kallen, T. Lander, and A. Stenzl Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: A first-in-man phase I/IIa study J. Immunother. Cancer 3 2015 26
19. N.J. Carter, and M.P. Curran Live attenuated influenza vaccine (FluMist®; fluenz™) Drugs 71 2011 1591 1622
20. J. Bienenstock, and M.R. McDermott Bronchus-and nasal-associated lymphoid tissues Immunol. Rev. 206 2005 22 31
21. J. Holmgren, and C. Czerkinsky Mucosal immunity and vaccines Nat. Med. 11 2005 S45 S53
22. P. Brandtzaeg Function of mucosa-associated lymphoid tissue in antibody formation Immunol. Investig. 39 2010 303 355
23. A. Gebril, M. Alsaadi, R. Acevedo, A.B. Mullen, and V.A. Ferro Optimizing efficacy of mucosal vaccines 2012
24. J. Brooking, S.S. Davis, and L. Illum Transport of nanoparticles across the rat nasal mucosa J. Drug Target. 9 2001 267 279
25. Q. Liu, X. Chen, J. Jia, W. Zhang, T. Yang, L. Wang, and G. Ma pH-responsive Poly(d,l-lactic-co-glycolic acid) nanoparticles with rapid antigen release behavior promote immune response ACS Nano 9 2015 4925 4938
26. M.L. Read, S. Singh, Z. Ahmed, M. Stevenson, S.S. Briggs, D. Oupicky, L.B. Barrett, R. Spice, M. Kendall, and M. Berry A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids Nucleic Acids Res. 33 2005 e86-e86
27. X. Su, J. Fricke, D.G. Kavanagh, and D.J. Irvine In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles Mol. Pharm. 8 2011 774 787
28. F.T. Zohra, E.H. Chowdhury, and T. Akaike High performance mRNA transfection through carbonate apatite-cationic liposome conjugates Biomaterials 30 2009 4006 4013
29. W. De Haes, G. Van Mol, C.l. Merlin, S.C. De Smedt, G. Vanham, and J. Rejman Internalization of mRNA lipoplexes by dendritic cells Mol. Pharm. 9 2012 2942 2949
30. P. Midoux, and C. Pichon Lipid-based mRNA vaccine delivery systems Expert Rev. Vaccines 14 2015 221 234
31. K.K. Phua, H.F. Staats, K.W. Leong, and S.K. Nair Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity Sci. Rep. 4 2014 5128
32. G. Ranaldi, I. Marigliano, I. Vespignani, G. Perozzi, and Y. Sambuy The effect of chitosan and other polycations on tight junction permeability in the human intestinal caco-2 cell line1 J. Nutr. Biochem. 13 2002 157 167
33. H. Debus, P. Baumhof, J. Probst, and T. Kissel Delivery of messenger RNA using poly(ethylene imine)-poly(ethylene glycol)-copolymer blends for polyplex formation: Biophysical characterization and in vitro transfection properties J. Control. Release 148 2010 334 343
34. F. Merkus, J. Verhoef, E. Marttin, S. Romeijn, P. Van der Kuy, W. Hermens, and N. Schipper Cyclodextrins in nasal drug delivery Adv. Drug Deliv. Rev. 36 1999 41 57
35. R.U. Agu, M. Jorissen, T. Willems, G. Van den Mooter, R. Kinget, N. Verbeke, and P. Augustijns Safety assessment of selected cyclodextrins - effect on ciliary activity using a human cell suspension culture model exhibiting in vitro ciliogenesis Int. J. Pharm. 193 2000 219 226
36. S.H. Pun, N.C. Bellocq, A. Liu, G. Jensen, T. Machemer, E. Quijano, T. Schluep, S. Wen, H. Engler, and J. Heidel Cyclodextrin-modified polyethylenimine polymers for gene delivery Bioconjug. Chem. 15 2004 831 840
37. G. Tang, H. Guo, F. Alexis, X. Wang, S. Zeng, T. Lim, J. Ding, Y. Yang, and S. Wang Low molecular weight polyethylenimines linked by β-cyclodextrin for gene transfer into the nervous system J. Gene Med. 8 2006 736 744
38. H. Asanuma, A.H. Thompson, T. Iwasaki, Y. Sato, Y. Inaba, C. Aizawa, T. Kurata, and S.-i. Tamura Isolation and characterization of mouse nasal-associated lymphoid tissue J. Immunol. Methods 202 1997 123 131
39. K. Sonaje, K.J. Lin, M.T. Tseng, S.P. Wey, F.Y. Su, E.Y. Chuang, C.W. Hsu, C.T. Chen, and H.W. Sung Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins Biomaterials 32 2011 8712 8721
40. Y. Jiang, M. Li, Z. Zhang, T. Gong, and X. Sun Enhancement of nasal HIV vaccination with adenoviral vector-based nanocomplexes using mucoadhesive and DC-targeting adjuvants Pharm. Res. 31 2014 2748 2761
41. C. Witschi, and R.J. Mrsny In vitro evaluation of microparticles and polymer gels for use as nasal platforms for protein delivery Pharm. Res. 16 1999 382 390
42. K.A. Foster, M.L. Avery, M. Yazdanian, and K.L. Audus Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery Int. J. Pharm. 208 2000 1 11
43. I. Richard, M. Thibault, G. De Crescenzo, M.D. Buschmann, and M. Lavertu Ionization behavior of chitosan and chitosan-DNA polyplexes indicate that chitosan has a similar capability to induce a proton-sponge effect as PEI Biomacromolecules 14 2013 1732 1740
44. K. Ohtake, T. Maeno, H. Ueda, M. Ogihara, H. Natsume, and Y. Morimoto Poly-l-arginine enhances paracellular permeability via serine/threonine phosphorylation of ZO-1 and tyrosine dephosphorylation of occludin in rabbit nasal epithelium Pharm. Res. 20 2003 1838 1845
45. K. Karikó, H. Ni, J. Capodici, M. Lamphier, and D. Weissman mRNA is an endogenous ligand for toll-like receptor 3 J. Biol. Chem. 279 2004 12542 12550
46. M. Fotin-Mleczek, K.M. Duchardt, C. Lorenz, R. Pfeiffer, S. Ojkic-Zrna, J. Probst, and K.-J. Kallen Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity J. Immunother. 34 2011 1 15
47. O. Andries, M. De Filette, S.C. De Smedt, J. Demeester, M. Van Poucke, L. Peelman, and N.N. Sanders Innate immune response and programmed cell death following carrier-mediated delivery of unmodified mRNA to respiratory cells J. Control. Release 167 2013 157 166
48. M.I. Ugwoke, R.U. Agu, N. Verbeke, and R. Kinget Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives Adv. Drug Deliv. Rev. 57 2005 1640 1665
49. H. Bshara, R. Osman, S. Mansour, and A.E.-H.A. El-Shamy Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats Carbohydr. Polym. 99 2014 297 305
50. F. Wegmann, K.H. Gartlan, A.M. Harandi, S.A. Brinckmann, M. Coccia, W.R. Hillson, W.L. Kok, S. Cole, L.P. Ho, T. Lambe, M. Puthia, C. Svanborg, E.M. Scherer, G. Krashias, A. Williams, J.N. Blattman, P.D. Greenberg, R.A. Flavell, A.E. Moghaddam, N.C. Sheppard, and Q.J. Sattentau Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens Nat. Biotechnol. 30 2012 883 888
51. Y. Wu, W. Wei, M. Zhou, Y. Wang, J. Wu, G. Ma, and Z. Su Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization Biomaterials 33 2012 2351 2360